These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16715137)

  • 1. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
    Riedemann J; Sohail M; Macaulay VM
    Biochem Biophys Res Commun; 2007 Apr; 355(3):700-6. PubMed ID: 17320820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
    Niu J; Xu Z; Li XN; Han Z
    Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
    Cui Y; Guadagno TM
    Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
    Christensen C; Guldberg P
    Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
    Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.